o A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927, an Immunotherapy, in Subjects with Advanced Solid Tumors (M15-862)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o An open label, Phase 1, first-in-human study of the safety and tolerability of TRAIL receptor agonist ABBV-621 in subjects with previously-treated solid tumors and hematologic malignancies (M15-913).
Investigador Principal: Dr. Emiliano Calvo Aller
Más información aquí
o A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer (M19-611)
Investigador Principal: Dr. Mª José de Miguel
Más información aquí
o A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (M19-894)
Investigador Principal: Dr. Irene Moreno
Más información aquí
o A Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab (MASTERKEY-318) (20140318).
Investigador Principal: Dr. Antonio Cubillo Gracián
Más información aquí
o A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND EFFICACY OF ADP-A2M4CD8 IN HLA-A2+ SUBJECTS WITH MAGE-A4 POSITIVE TUMORS (ADP005-001)
Investigador Principal: Dr. Emiliano Calvo
o A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors- ARTISTRY-1 (ALK4230-A101 (ARTISTRY-1))
Investigador Principal: Dr. Valentina Boni
Más información aquí
o A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors (BGB-290-103).
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o “Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer (the LUPER study).”
Investigador Principal: Dr. Mª José de Miguel
Más información aquí
o Subjects With Advanced Solid Tumors in Phase 2 (MASTERKEY-318) With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat (APX005M-010)
Investigador Principal: Dr. Valentina Boni
Más información aquí
o A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma (APX005M-002)
Investigador Principal: Dra. Valentina Boni
Más información aquí
o An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered with Encorafenib and Binimetinib in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (ARRAY_818-103)
Investigador Principal: Dr. Mª José de Miguel
Más información aquí
o A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in
Subjects with Advanced Solid Tumors (8374-CL-0101)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC‑9545 Alone or In Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced OR Metastatic Estrogen Receptor-Positive Breast Cancer (GO39932).
Investigador Principal: Dra. Valentina Boni
Más información aquí
o An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma (H3B6527-G000-101).
Investigador Principal: Dra. María José de Miguel Luken
o An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia (H3B-8800-G000-101).
Investigador Principal: Dr. Jaime Pérez de Oteyza
Más información aquí
o A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer (D8530C00001)
Investigador Principal: Dra. Valentina Boni
Más información aquí
o Phase 1/2 Study Investigating Safety, Tolerability, Pharmacokinetics andPreliminary Antitumor Activity of Anti-PD-L1 Monoclonal AntibodyBGB-A333 Alone and in Combination with Anti-PD-1 MonoclonalAntibody BGB-A317 in Patients with Advanced Solid Tumors (BGB-900-101)
Investigador Principal: Dr. Emiliano Calvo Aller
Más información aquí
o Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (BNT411-01)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o JPhase I, first in human trial evaluating BI 1387446 alone and in combination with BI 754091 in solid tumors (BI1426-0001)
Investigador Principal: Dr. Emiliano Calvo Aller
Más información aquí
o An open label, Phase I dose-finding study of BI 754111 in combination with BI 754091 inpatients with advanced solid cancers and of BI 754111 monotherapy with subsequent combination with BI 754091 in patients with follicular lymphoma, followed by expansion cohorts at the RPIID of thecombination in patients with non-small cell lung cancer, metastatic colorectal cancer, solid tumors with high tumour mutational burden and/or microsatellite instability (1381.2)
Investigador Principal: Dra. Mª Jose de Miguel
o A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC) (BOS172738-01)
Investigador Principal: Dra. Valentina Boni
Más información aquí
o A Phase I/IIa Trial with BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors. (CA011-001)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety andTolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or inCombination with Nivolumab or Ipilimumab in Patients with Advanced Solid Tumors (CA021-002)
Investigador Principal:
Dr. Emiliano Calvo
Más información aquí
o BMS-986218 Monoclonal Antibody Alone and inCombination with Nivolumab (CA022-001)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered inCombination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 MonoclonalAntibody) in Advanced Malignant Tumors (CA224-0048)
Investigador Principal: Dr. Emiliano Calvo Aller
Más información aquí
o Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029) (CTMX-M-2029-001)
Investigador Principal: Dra. Valentina Boni
Más información aquí
o A Phase 1b Dose Escalation, Multicenter, Open-label Study to evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in SUBJECTS with advanced solid tumors and relapsed/refractory diffuse large b-cell lymphoma (CC-95775-ST-001)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o A PHASE 1B, MULTICENTER, TWO-PART, OPEN-LABEL STUDY OF DS-8201A, AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2)-ANTIBODY DRUG CONJUGATE (ADC), IN COMBINATION WITH NIVOLUMAB, AN ANTI-PD-1 ANTIBODY, FOR SUBJECTS WITH HER2-EXPRESSING ADVANCED BREASTAND UROTHELIAL CANCER (DS8201-A-U105)
Investigador Principal: Dra. Valentina Boni
Más información aquí
o Debio 1143 a SMAC Mimetic in Combination with Nivolumab inPatients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial (1143-106)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o A multicenter Phase 1a/1b study of safety, tolerability, whole-body radio-distribution, and radiation dosimetry of Debio 1124 in patients with advanced, unresectable pulmonary and extrapulmonary small cell carcinoma (1124-102)
Investigador Principal: Dr. Emiliano Calvo
o .A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects with Advanced Solid Tumours (FP1305)
Investigador Principal: Dra. María José de Miguel Luken
Más información aquí
o A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects with Advanced Solid Tumours (GCT1029-01)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors (GCT1046-01)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o A PHASE Ia/Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB ADMINISTERED WITH AND WITHOUT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS (GO30103)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o PHASE I MULTICENTER, OPEN LABEL PREOPERATIVE SHORT TERM WINDOW STUDY OF GDC-9545 IN POST MENOPAUSAL WOMEN WITH STAGE I - III OPERABLE, ESTROGEN RECEPTOR POSITIVE BREAST CANCER. (GO40987)
Investigador Principal: Dra. Valentina Boni
Más información aquí
o A PHASE Ib DOSE-ESCALATION AND DOSEEXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VENETOCLAX IN COMBINATION WITH ATEZOLIZUMAB, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER (GO41864)
Investigador Principal: Dra. M. Jose de Miguel
Más información aquí
o A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NYESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer (GSK2078471)
Investigador Principal: Dr. Emiliano Calvo
o A Phase I/II, Open-label, Dose Escalation and Expansion Study to EvaluateSafety, Tolerability, and Clinical Activity of the Antibody-Drug ConjugateGSK2857916 Administered in Combination with Lenalidomide PlusDexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) inParticipants with Relapsed / Refractory Multiple Myeloma – DREAMM-6 (GSK207497)
Investigador Principal: Dr. Jaime Perez de Oteyza
o A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3368715 in participants with solid tumors and DLBCL (GSK207675)
Investigador Principal: Dr. Emiliano Calvo
o A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination with Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Subjects With Previously Treated B-Cell Lymphoma (CITADEL-112) (INCB50465-112)
Investigador Principal: Dr. Jaime Perez de Oteyza
Más información aquí
o A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, aHuman Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small CellLung Cancer (61186372EDI1001)
Investigador Principal: Dra. Maria Jose de Miguel
Más información aquí
o A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (64091742PCR2002)
Investigador Principal: Dra. Valentina Boni
Más información aquí
o A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors (70218902EDI1001)
Investigador Principal: Dr.Emiliano Calvo
Más información aquí
o Estudio Fase I/Ib abierto para evaluar la seguridad y farmacocinética de JNJ-73841937 (lazertinib), un inhibidor de la tirosinaquinasa del EGFR (TKI-EGFR) de tercera generación, en monoterapia o en combinación con JNJ-61186372, un anticuerpo humano biespecífico frente a EGFR y cMet, en pacientes con cáncer de pulmón no microcítico avanzado (73841937NC1001)
Investigador Principal: Dra. M.Jose de Miguel
o An Open-label, Phase 1 Study of KHK2455 in Combination with Avelumab in Adult Subjects with Locally Advanced or Metastatic Urothelial Carcinoma (KIOWA KIRIN 2455-002)
Investigador Principal: Dra. Irene Montero
Más información aquí
o A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201) (LOXO-RET-18037)
Investigador Principal: Dra. Valentina Boni
o A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 (formerly MGA012) in Patients with Advanced Solid Tumors (POD1UM-101) (CP-MGA012-01)
Investigador Principal: Dra. M.Jose de Miguel
o A Phase 1, First-in-Human, Open-Label, Dose Escalation Study ofMGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 inPatients with Unresectable or Metastatic Neoplasms (CP-MGD013-01)
Investigador Principal: Dra. M.Jose de Miguel
Más información aquí
o OPEN-LABEL,MULTICENTRE, PHASE IB/II STUDY OF MEN1611, A PI3K INHIBITOR, AND CETUXIMAB IN PATIENTS WITH PIK3CA MUTATED METASTATIC COLORECTAL CANCER FAILING IRINOTECAN, OXALIPLATIN, 5-FU AND ANTI-EGFR CONTAINING REGIMENS (MEN1611-02)
Investigador Principal: Dra. M.Jose de Miguel
Más información aquí
o THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. (MSD).(MK4830-01)
Investigador Principal: Dra. M.Jose de Miguel
o A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors (MCLA-128-CL01)
Investigador Principal: Dra. M.Jose de Miguel
Más información aquí
o Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatinineligible locally advanced HNSCC patients (NBTXR3-102)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (16-214-05), AMENDMENT6.0, 10FEB2020 (NEKTAR-PROPEL-16-214-05)
Investigador Principal: Dra. M.Jose de Miguel
o A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands (CLGK974X2101)
Investigador Principal: Dr. M.Jose de Miguel
Más información aquí
o Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapy in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma (CVPM087A2101)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients with Advanced Solid Tumors (ODO-S-101)
Investigador Principal: Dr. Emiliano Calvo
o A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE AND NEGATIVE SOLID TUMORS (CO541001)
Investigador Principal: Dr. Emiliano Calvo
o A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OFPF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITHRELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC),CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULARLYMPHOMA (FL) (C2321001)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o An Open-Label, Multicenter Study to Assess the Potential Effects of Itraconazole (a Strong CYP3A4 Inhibitor) on the Pharmacokinetics of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors (PM1183-A-018-20)
Investigador Principal: Dr. Irene Montero
o ”Her-Seq: Estudio de cribado en sangre para identificar a pacientes con mutación en HER2 para su inclusión en estudios de investigación clínica sobre el neratinib”. (PUMA-NER-9501)
Investigador Principal: Dra. Valentina Boni
Más información aquí
o ”Her-Seq: Estudio de cribado en sangre para identificar a pacientes con mutación en HER2 para su inclusión en estudios de investigación clínica sobre el neratinib”. (PUMA-NER-5201)
Investigador Principal: Dra. Valentina Boni
Más información aquí
o An Open-Label, Phase 2 Basket Study of Neratinib in Patients with Solid Tumors with Somatic Activating HER Mutations (BO39610)
Investigador Principal: Dra. Valentina Boni
Más información aquí
o AN OPEN LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD SPONSORED ATEZOLIZUMAB STUDY (IMBRELLA B) (BO40729)
Investigador Principal: Dr. Emiliano Calvo
Más información aquí
o DOSE-ESCALATION, PHASE IA/IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF RO7122290, A FIBROBLAST ACTIVATION PROTEIN- (FAP) TARGETED 4-1BB LIGAND (CD137L), WITH OR WITHOUT OBINUTUZUMAB PRE-TREATMENT, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS AS SINGLE AGENT OR IN COMBINATION WITH ATEZOLIZUMAB FOLLOWED BY TUMOR SPECIFIC EXPANSION COHORT(S) (BP40087)
Investigador Principal: Dr. Emiliano Calvo
o AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH ATEZOLIZUMAB (ANTI-PD-L1), ADMINISTERED INTRAVENOUSLY, IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS (BP40234)
Investigador Principal: Dr. Mª José de Miguel
Más información aquí